{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=37",
    "query": {
      "intervention": "combined therapy treatment",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 12519,
    "total_pages": 1252,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T05:01:20.063Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07049159",
      "title": "Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Shigella"
      ],
      "interventions": [
        {
          "name": "ShigETEC vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Eveliqure Biotechnologies GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 72,
      "start_date": "2025-06-30",
      "completion_date": "2027-05-23",
      "has_results": false,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-10-16T05:01:20.063Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07049159"
    },
    {
      "nct_id": "NCT03223662",
      "title": "Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Esophageal Adenocarcinoma",
        "Esophageal Squamous Cell Cancer",
        "Esophageal Neoplasms",
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Chemoradiotherapy",
          "type": "OTHER"
        },
        {
          "name": "Esophagectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-10-31",
      "completion_date": "2018-07-27",
      "has_results": true,
      "last_update_posted_date": "2018-10-30",
      "last_synced_at": "2026-10-16T05:01:20.063Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03223662"
    },
    {
      "nct_id": "NCT06457503",
      "title": "A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nasopharyngeal Cancer Recurrent"
      ],
      "interventions": [
        {
          "name": "Toripalimab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Coherus Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-11-01",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-16T05:01:20.063Z",
      "location_count": 12,
      "location_summary": "Little Rock, Arkansas • Irvine, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06457503"
    },
    {
      "nct_id": "NCT04126070",
      "title": "Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone Sensitive Prostate Cancer",
        "Prostate Adenocarcinoma",
        "Metastasis Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Androgen Deprivation Therapy",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xiao X. Wei, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 47,
      "start_date": "2020-05-11",
      "completion_date": "2026-10-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-16T05:01:20.063Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04126070"
    },
    {
      "nct_id": "NCT02281760",
      "title": "Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BRAF V600E Mutation"
      ],
      "interventions": [
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Trametinib Dimethyl Sulfoxide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 9,
      "start_date": "2014-11-01",
      "completion_date": "2018-08-29",
      "has_results": true,
      "last_update_posted_date": "2021-08-31",
      "last_synced_at": "2026-10-16T05:01:20.063Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281760"
    },
    {
      "nct_id": "NCT01026727",
      "title": "A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MPC-4326 plus a 2-3 drug optimized background regimen (OBR)",
          "type": "DRUG"
        },
        {
          "name": "3-4 commercially available antiretroviral drugs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myrexis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2009-11",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2010-06-14",
      "last_synced_at": "2026-10-16T05:01:20.063Z",
      "location_count": 21,
      "location_summary": "Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01026727"
    },
    {
      "nct_id": "NCT00740961",
      "title": "Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Cognitive/Functional Effects",
        "Colorectal Cancer",
        "Psychosocial Effects of Cancer and Its Treatment"
      ],
      "interventions": [
        {
          "name": "compliance monitoring",
          "type": "BEHAVIORAL"
        },
        {
          "name": "systemic chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "medical chart review",
          "type": "OTHER"
        },
        {
          "name": "study of socioeconomic and demographic variables",
          "type": "OTHER"
        },
        {
          "name": "survey administration",
          "type": "OTHER"
        },
        {
          "name": "cognitive assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "psychosocial assessment and care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2008-03",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2020-07-27",
      "last_synced_at": "2026-10-16T05:01:20.063Z",
      "location_count": 5,
      "location_summary": "Cleveland, Ohio • Mentor, Ohio • Orange, Ohio + 2 more",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Mentor",
          "state": "Ohio"
        },
        {
          "city": "Orange",
          "state": "Ohio"
        },
        {
          "city": "South Euclid",
          "state": "Ohio"
        },
        {
          "city": "Westlake",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00740961"
    },
    {
      "nct_id": "NCT01068873",
      "title": "Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "lopinavir/ritonavir plus maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Temple University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2010-04",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2020-11-02",
      "last_synced_at": "2026-10-16T05:01:20.063Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068873"
    },
    {
      "nct_id": "NCT00002382",
      "title": "A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Saquinavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 4000,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-16T05:01:20.063Z",
      "location_count": 1,
      "location_summary": "Nutley, New Jersey",
      "locations": [
        {
          "city": "Nutley",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002382"
    },
    {
      "nct_id": "NCT00478062",
      "title": "Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Hodgkin's antigens-GM-CSF-expressing cell vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-04",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2018-02-28",
      "last_synced_at": "2026-10-16T05:01:20.063Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00478062"
    }
  ]
}